Mirum Pharmaceuticals, Inc.
MIRM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001759425
In the last 90 days, Mirum Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 328 institutions reported holding it in 13F filings for Q2 2026, worth $8.36B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:21 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $23.4M (4.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Revenue | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M |
| Operating expenses | $543.4M | $424.5M | $295.5M | $208.3M | $192.6M |
| Research and development | $186.2M | $140.6M | $102.6M | $106.8M | $131.4M |
| Selling, general and administrative | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M |
| Operating income | -$22.1M | -$87.6M | -$109.2M | -$131.2M | -$173.4M |
| Income tax | $1.94M | $1.03M | $991.0K | -$6.41M | $37.0K |
| Net income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M |
| EPS, basic | $-0.47 | $-1.85 | $-4.00 | $-4.01 | – |
| EPS, diluted | $-0.47 | $-1.85 | $-4.00 | $-4.02 | – |
| Weighted shares, basic | 50.2M | 47.5M | 40.9M | 33.8M | – |
| Weighted shares, diluted | 50.2M | 47.5M | 40.9M | 34.0M | – |
| Margins and growth | |||||
| Operating margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% |
| Net margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% |
| Revenue growth, year over year | +54.7% | +80.8% | +141.8% | +302.7% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Cash and equivalents | $296.7M | $222.5M | $286.3M | $28.0M | $31.3M |
| Short-term investments | $86.6M | $57.8M | $0 | $123.7M | $125.2M |
| Accounts receivable | $123.3M | $78.3M | $68.0M | $24.0M | $3.27M |
| Inventory | $24.9M | $22.4M | $22.3M | $5.57M | $1.51M |
| Total current assets | $549.7M | $392.8M | $387.5M | $190.2M | $166.6M |
| Property, plant and equipment | $1.86M | $1.14M | $706.0K | $914.0K | $981.0K |
| Intangible assets | $260.9M | $249.8M | $252.9M | $59.0M | $18.7M |
| Total assets | $842.8M | $670.8M | $646.6M | $352.9M | $294.7M |
| Accounts payable | $9.61M | $14.6M | $7.42M | $8.69M | $9.17M |
| Total current liabilities | $205.8M | $126.6M | $87.1M | $64.7M | $42.6M |
| Total liabilities | $528.1M | $445.1M | $398.0M | $210.9M | $174.4M |
| Shareholders' equity | $314.7M | $225.6M | $248.7M | $142.0M | $120.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 11, 2022 |
| Operating cash flow | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M |
| Capital expenditures | $954.0K | $993.0K | $109.0K | $278.0K | $24.0K |
| Free cash flow | $54.9M | $9.33M | -$71.1M | -$120.4M | -$132.8M |
| Depreciation and amortization | $24.2M | $23.6M | $10.8M | $3.24M | $595.0K |
| Stock-based compensation | $71.4M | $48.4M | $35.0M | $27.0M | $23.1M |
| Investing cash flow | -$24.0M | -$90.1M | -$107.2M | $7.70M | $48.5M |
| Financing cash flow | $40.1M | $17.7M | $336.6M | $109.1M | $73.5M |
| Net change in cash | $75.2M | -$63.4M | $158.3M | -$3.34M | -$10.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 13.7% | 14.4% | 18.8% | 35.0% | 120.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 65.3M | +27.0% | SEC |
| Jul 31, 2026 | 64.9M | +29.3% | SEC |
| May 1, 2026 | 61.0M | +23.1% | SEC |
| Feb 20, 2026 | 60.3M | +23.1% | SEC |
| Oct 31, 2025 | 51.4M | +7.1% | SEC |
| Aug 1, 2025 | 50.2M | +5.3% | SEC |
| May 2, 2025 | 49.5M | +5.1% | SEC |
| Feb 21, 2025 | 49.0M | +4.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.